PTPN2 (P17706) variants and mutations
PTPN2 (also known as P17706) is a human protein-coding gene encoding a tyrosine-protein phosphatase non-receptor type 2 protein. It restrains cytokine and growth-factor signaling by dephosphorylating JAK-STAT and related pathway components. Haploinsufficiency can cause early-onset immune dysregulation with autoimmunity, while common variants influence inflammatory bowel disease and other autoimmune risks. This analysis covers 651 PTPN2 variants and mutations. Of these, 81% have computational variant effect predictions. Disease context includes rheumatoid arthritis, type 1 diabetes mellitus, and inflammatory bowel disease. Example PTPN2 variants include P2H, P2L, and P2R.
Variant analysis overview
- Gene: PTPN2
- Protein: P17706
- UniProt accession: P17706
- Organism: Homo sapiens
- Variants analyzed: 651
- Variant scope: all variants
- Completed: 2026-08-21
Variant and mutation evidence
- Variant composition: 412 unspecified-consequence records; 83 synonymous variants; 120 missense variants; 23 frameshift variants; 7 in-frame deletions; 6 stop-gained variants; 1 splice-region variants; 1 in-frame insertions; 1 protein altering variant
- Prediction scores: 525 variants have prediction scores (81% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: rheumatoid arthritis, type 1 diabetes mellitus, inflammatory bowel disease, Crohn disease, autoimmune disease, psoriasis, systemic lupus erythematosus, hypothyroidism, Arthritis, arthritic joint disease, celiac disease, common variable immunodeficiency.
Protein structure and variant hotspots
- Protein features: 1 domains; 3 binding sites; 8 post-translational modification sites.
- Structural context: 341 variants have structural context.
- PTM context: 10 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable PTPN2 variants
Examples include P2H, P2L, P2R, P2S, T3A, T3I, T3S, T4A. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- P2H (p.Pro2His), ExAC rs771614274, TOPMed rs771614274, gnomAD rs771614274, REVEL 0.09, CADD 22.70
- P2L (p.Pro2Leu), ExAC rs771614274, TOPMed rs771614274, gnomAD rs771614274, REVEL 0.07, CADD 20.50
- P2R (p.Pro2Arg), ExAC rs771614274, TOPMed rs771614274, gnomAD rs771614274
- P2S (p.Pro2Ser), rs867096066, NCI-TCGA Cosmic COSV1005, cosmic curated COSV10051, TOPMed rs867096066, REVEL 0.03, CADD 9.56, Variant assessed as somatic; moderate impact.
- T3A (p.Thr3Ala), TOPMed rs1385843772, gnomAD rs1385843772, REVEL 0.01, CADD 8.47
- T3I (p.Thr3Ile), TOPMed rs1276711486, gnomAD rs1276711486, REVEL 0.02, CADD 12.40
- T3S (p.Thr3Ser), TOPMed rs1385843772, gnomAD rs1385843772, REVEL 0.01, CADD 6.60
- T4A (p.Thr4Ala), TOPMed rs945467973, REVEL 0.02, CADD 3.24
- T4I (p.Thr4Ile), ExAC rs747486746, gnomAD rs747486746, REVEL 0.08, CADD 12.00
- T4N (p.Thr4Asn), ExAC rs747486746, gnomAD rs747486746, REVEL 0.06, CADD 7.33
- T4S (p.Thr4Ser), TOPMed rs945467973, REVEL 0.06, CADD 6.38
- E6K (p.Glu6Lys), ExAC rs778310630, TOPMed rs778310630, gnomAD rs778310630, REVEL 0.19, CADD 22.70
- E6V (p.Glu6Val), ExAC rs758737273, gnomAD rs758737273, REVEL 0.15, CADD 23.70
- R7W (p.Arg7Trp), gnomAD rs1226346253, REVEL 0.15, CADD 24.60
- E8D (p.Glu8Asp), ESP rs150641661, ExAC rs150641661, TOPMed rs150641661, gnomAD rs150641661, REVEL 0.14, CADD 22.90
- E8K (p.Glu8Lys), TOPMed rs1337353757, gnomAD rs1337353757, REVEL 0.19, CADD 23.30, Uncertain significance, not specified
- E8Q (p.Glu8Gln), TOPMed rs1337353757, gnomAD rs1337353757, REVEL 0.12, CADD 24.10
- E8V (p.Glu8Val), gnomAD rs1451616383, REVEL 0.16, CADD 23.80
- F9C (p.Phe9Cys), Ensembl rs1598913685
- F9V (p.Phe9Val), Ensembl rs1598913694
- E10D (p.Glu10Asp), gnomAD rs1568185242, REVEL 0.07, CADD 16.50
- E11D (p.Glu11Asp), TOPMed rs1395399977, gnomAD rs1395399977, REVEL 0.06, CADD 14.70
- E11K (p.Glu11Lys), 1000Genomes rs200164592, ExAC rs200164592, TOPMed rs200164592, gnomAD rs200164592, REVEL 0.18, CADD 22.50
- E11Q (p.Glu11Gln), cosmic curated COSV10051, 1000Genomes rs200164592, ExAC rs200164592, TOPMed rs200164592, REVEL 0.10, CADD 20.70
- L12F (p.Leu12Phe), Ensembl rs867997369, REVEL 0.03, CADD 22.40
- L12S (p.Leu12Ser), gnomAD rs1445972788, REVEL 0.17, CADD 23.60
- L12V (p.Leu12Val), ExAC rs754585398, TOPMed rs754585398, gnomAD rs754585398
- T14A (p.Thr14Ala), ESP rs369944958, ExAC rs369944958, TOPMed rs369944958, gnomAD rs369944958, REVEL 0.02, CADD 11.30, Likely benign, not specified
- T14N (p.Thr14Asn), gnomAD rs1184779249, REVEL 0.11, CADD 20.20
- T14S (p.Thr14Ser), gnomAD rs1184779249, REVEL 0.11, CADD 16.10
- Q15H (p.Gln15His), TOPMed rs1466257016, gnomAD rs1466257016, REVEL 0.04, CADD 15.60
- R16C (p.Arg16Cys), gnomAD rs1236087183, REVEL 0.05, CADD 21.50
- R16H (p.Arg16His), cosmic curated COSV58997, TOPMed rs1206823913, gnomAD rs1206823913, REVEL 0.04, CADD 22.70
- R16L (p.Arg16Leu), TOPMed rs1206823913, gnomAD rs1206823913, REVEL 0.07, CADD 22.70, Uncertain significance, not specified
- R17C (p.Arg17Cys), NCI-TCGA Cosmic COSV5899, cosmic curated COSV58996, REVEL 0.06, CADD 22.50, Variant assessed as somatic; moderate impact.
- R17G (p.Arg17Gly), gnomAD rs1438599484, REVEL 0.08, CADD 18.80
- R17H (p.Arg17His), TOPMed rs1272652429, gnomAD rs1272652429, REVEL 0.05, CADD 22.90
- Q19* (p.Gln19Ter), TOPMed rs1203075385, gnomAD rs1203075385, CADD 42.00
- P20L (p.Pro20Leu), rs562857102, ClinGen CA402035672, ClinVar RCV004133080, REVEL 0.03, CADD 20.00, Uncertain significance, not specified
- P20Q (p.Pro20Gln), 1000Genomes rs562857102, ExAC rs562857102, gnomAD rs562857102, REVEL 0.03, CADD 17.40
- P20R (p.Pro20Arg), cosmic curated COSV58999, 1000Genomes rs562857102, ExAC rs562857102, gnomAD rs562857102, REVEL 0.04, CADD 18.10
- P20S (p.Pro20Ser), TOPMed rs1361746465, gnomAD rs1361746465, REVEL 0.03, CADD 15.20
- L21V (p.Leu21Val), ExAC rs756085499, gnomAD rs756085499, REVEL 0.05, CADD 17.20
- Y22H (p.Tyr22His), gnomAD rs1281057841
- L23F (p.Leu23Phe), TOPMed rs1457235029, gnomAD rs1457235029, REVEL 0.06, CADD 23.20
- L23S (p.Leu23Ser), TOPMed rs2044773454, REVEL 0.21, CADD 22.40
- E24A (p.Glu24Ala), ExAC rs748912308, gnomAD rs748912308, REVEL 0.18, CADD 25.10
- I25V (p.Ile25Val), TOPMed rs1285609315, gnomAD rs1285609315, REVEL 0.09, CADD 23.00
- R26* (p.Arg26Ter), NCI-TCGA Cosmic COSV5899, cosmic curated COSV58996, TOPMed rs2043704722, CADD 38.00, Variant assessed as somatic; high impact.
- R26L (p.Arg26Leu), ExAC rs779572195, gnomAD rs779572195
- N27I (p.Asn27Ile), TOPMed rs950185463, gnomAD rs950185463, REVEL 0.10, CADD 23.40, Uncertain significance
- N27S (p.Asn27Ser), rs950185463, ClinGen CA296769472, ClinVar RCV004280936, TOPMed rs950185463, REVEL 0.08, CADD 20.10, Uncertain significance, not specified
- E28K (p.Glu28Lys), NCI-TCGA Cosmic COSV5899, cosmic curated COSV58999, Variant assessed as somatic; moderate impact.
- S29F (p.Ser29Phe), gnomAD rs1266017550, REVEL 0.43, CADD 29.00
- H30N (p.His30Asn), cosmic curated COSV10051, ExAC rs755572904, TOPMed rs755572904, gnomAD rs755572904, REVEL 0.09, CADD 18.90
- H30R (p.His30Arg), gnomAD rs917217934, REVEL 0.06, CADD 19.30
- D31G (p.Asp31Gly), Ensembl rs950936929
- D31Y (p.Asp31Tyr), TOPMed rs2043703786
- Y32C (p.Tyr32Cys), cosmic curated COSV10737, TOPMed rs1027932038, gnomAD rs1027932038, REVEL 0.07, CADD 22.70
- P33L (p.Pro33Leu), cosmic curated COSV10963, gnomAD rs1375809882, REVEL 0.18, CADD 23.20
- R35G (p.Arg35Gly), cosmic curated COSV58998, TOPMed rs2043703320, REVEL 0.14, CADD 24.70
- R35S (p.Arg35Ser), ExAC rs750374603, TOPMed rs750374603, gnomAD rs750374603, REVEL 0.08, CADD 24.20
- V36M (p.Val36Met), 1000Genomes rs537221478, ExAC rs537221478, TOPMed rs537221478, gnomAD rs537221478, REVEL 0.20, CADD 25.10
- A37V (p.Ala37Val), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- K38Q (p.Lys38Gln), gnomAD rs1291106111, REVEL 0.16, CADD 26.40
- F39L (p.Phe39Leu), TOPMed rs1432117963, gnomAD rs1432117963, REVEL 0.08, CADD 16.00
- P40L (p.Pro40Leu), gnomAD rs1172950151, REVEL 0.12, CADD 23.40
- E41D (p.Glu41Asp), gnomAD rs1318954462
- E41G (p.Glu41Gly), Ensembl rs2043702565, REVEL 0.17, CADD 27.90
- R43* (p.Arg43Ter), NCI-TCGA Cosmic COSV1005, cosmic curated COSV10051, Variant assessed as somatic; high impact.
- R43G (p.Arg43Gly), TOPMed rs2043702339
- N44D (p.Asn44Asp), ExAC rs763765476, gnomAD rs763765476, REVEL 0.33, CADD 23.90
- N44Y (p.Asn44Tyr), ExAC rs763765476, gnomAD rs763765476, REVEL 0.55, CADD 24.40
- R45* (p.Arg45Ter), NCI-TCGA Cosmic COSV1005, cosmic curated COSV10051, TOPMed rs2043702082, CADD 38.00, Variant assessed as somatic; high impact.
- R47G (p.Arg47Gly), NCI-TCGA Cosmic COSV1005, cosmic curated COSV10051, gnomAD rs2043701947, REVEL 0.89, CADD 27.70, Variant assessed as somatic; moderate impact.
- Y48* (p.Tyr48Ter), TOPMed rs1191212687, gnomAD rs1191212687, CADD 34.00
- Y48F (p.Tyr48Phe), ExAC rs759832705, gnomAD rs759832705, REVEL 0.76, CADD 27.50
- R49I (p.Arg49Ile), NCI-TCGA Cosmic COSV5899, Variant assessed as somatic; moderate impact.
- D55G (p.Asp55Gly), Ensembl rs913379921, REVEL 0.95, CADD 28.10
- R58C (p.Arg58Cys), NCI-TCGA Cosmic COSV1005, cosmic curated COSV10051, REVEL 0.86, CADD 32.00, Variant assessed as somatic; moderate impact.
- Q62E (p.Gln62Glu), gnomAD rs2042883804, REVEL 0.32, CADD 18.60
- N63S (p.Asn63Ser), TOPMed rs996337306, gnomAD rs996337306, REVEL 0.17, CADD 16.40
- E65* (p.Glu65Ter), NCI-TCGA Cosmic COSV1005, cosmic curated COSV10051, NCI-TCGA Cosmic COSV5899, Variant assessed as somatic; high impact.
- E65Q (p.Glu65Gln), NCI-TCGA Cosmic COSV1005, NCI-TCGA Cosmic COSV5899, cosmic curated COSV58999, Variant assessed as somatic; moderate impact.
- N66S (p.Asn66Ser), Ensembl rs2042883420
- D67N (p.Asp67Asn), Ensembl rs2042883262
- I69V (p.Ile69Val), Ensembl rs2042883173, REVEL 0.69, CADD 25.00
- S72N (p.Ser72Asn), gnomAD rs1455114748, REVEL 0.33, CADD 22.10
- V74L (p.Val74Leu), TOPMed rs1201944113
- I76T (p.Ile76Thr), Ensembl rs902050146
- I76V (p.Ile76Val), TOPMed rs2042882761, REVEL 0.19, CADD 14.50
- E77Q (p.Glu77Gln), cosmic curated COSV58998, ExAC rs752113628, gnomAD rs752113628, REVEL 0.45, CADD 23.70
- E78D (p.Glu78Asp), NCI-TCGA Cosmic COSV1005, cosmic curated COSV10051, ExAC rs764654245, TOPMed rs764654245, Variant assessed as somatic; moderate impact.
- A79G (p.Ala79Gly), TOPMed rs953123344, REVEL 0.54, CADD 25.80
- A79S (p.Ala79Ser), Ensembl rs2042882265
- A79T (p.Ala79Thr), NCI-TCGA Cosmic COSV5899, cosmic curated COSV58995, REVEL 0.44, CADD 25.30, Variant assessed as somatic; moderate impact.
- Q80H (p.Gln80His), ExAC rs763426003, gnomAD rs763426003, REVEL 0.33, CADD 11.10
- Q80P (p.Gln80Pro), Ensembl rs2042881969, REVEL 0.51, CADD 20.30
- R81G (p.Arg81Gly), Ensembl rs2042881711
- R81T (p.Arg81Thr), NCI-TCGA Cosmic COSV5899, cosmic curated COSV58995, Variant assessed as somatic; moderate impact.
- S82G (p.Ser82Gly), 1000Genomes rs74163638, ESP rs74163638, ExAC rs74163638, TOPMed rs74163638, REVEL 0.42, CADD 25.50
- S82R (p.Ser82Arg), 1000Genomes rs74163638, ESP rs74163638, ExAC rs74163638, TOPMed rs74163638, REVEL 0.18, CADD 21.60
- Y83H (p.Tyr83His), TOPMed rs943757284, gnomAD rs943757284, REVEL 0.85, CADD 28.40
- T86P (p.Thr86Pro), gnomAD rs1267220108, REVEL 0.88, CADD 25.90
- Q87=, NCI-TCGA TCGA novel, Variant assessed as somatic; low impact.
- G88C (p.Gly88Cys), gnomAD rs2042649573, REVEL 0.92, CADD 33.00
- P91L (p.Pro91Leu), rs566078683, gnomAD 18-12793569-G-A, CADD 12.30
- N92K (p.Asn92Lys), Ensembl rs1568124158, REVEL 0.48, CADD 23.20
- C94S (p.Cys94Ser), ExAC rs774373051, gnomAD rs774373051
- H96F (p.His96Phe), gnomAD 18-12793566-TGG-T, CADD 8.42
- H96Y (p.His96Tyr), gnomAD 18-12793567-G-A, CADD 10.50
- H96N (p.His96Asn), gnomAD 18-12793567-G-T, CADD 9.21
- F97L (p.Phe97Leu), ExAC rs768576389, TOPMed rs768576389, gnomAD rs768576389, REVEL 0.82, CADD 26.70
- F97S (p.Phe97Ser), rs1385254956, gnomAD 18-12793530-A-G, CADD 13.20
- F97I (p.Phe97Ile), rs1188209060, gnomAD 18-12793573-A-T, CADD 15.70
- L99F (p.Leu99Phe), TOPMed rs889010899, gnomAD rs889010899, REVEL 0.65, CADD 25.90
- V101I (p.Val101Ile), TOPMed rs1432576957, gnomAD rs1432576957, REVEL 0.23, CADD 17.90
- Q104E (p.Gln104Glu), rs957380233, gnomAD 18-12793542-CTTTG, CADD 6.57
- Q106del (p.Gln106del), rs2041048687, gnomAD 18-12793542-CTTT-, CADD 6.34
- Q104Q (p.Gln104Gln), gnomAD 18-12793544-T-C, CADD 7.76
- Q104K (p.Gln104Lys), gnomAD 18-12793546-G-T, CADD 2.21
- K105N (p.Lys105Asn), TOPMed rs2042648239, gnomAD rs2042648239, REVEL 0.22, CADD 19.50
- K105Q (p.Lys105Gln), gnomAD rs1408071596, REVEL 0.35, CADD 22.60
- K105K (p.Lys105Lys), gnomAD 18-12793547-T-C, CADD 11.10
- K105E (p.Lys105Glu), gnomAD 18-12793555-T-C, CADD 12.00
- K105* (p.Lys105Ter), gnomAD 18-12793561-T-TA, CADD 11.20
- T106S (p.Thr106Ser), gnomAD rs1336909079, REVEL 0.20, CADD 13.10, Uncertain significance, not specified
- K107Q (p.Lys107Gln), rs2041047919, gnomAD 18-12793537-T-G, CADD 6.97
- A108S (p.Ala108Ser), TOPMed rs1413571843, gnomAD rs1413571843, REVEL 0.74, CADD 25.90
- V109D (p.Val109Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- V110F (p.Val110Phe), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- M111I (p.Met111Ile), gnomAD rs1475479415, REVEL 0.91, CADD 26.00
- M111R (p.Met111Arg), ExAC rs779886860
- M111V (p.Met111Val), gnomAD rs1169141526, REVEL 0.94, CADD 25.40
- L112Q (p.Leu112Gln), gnomAD rs2042647498, REVEL 0.95, CADD 28.10
- N113I (p.Asn113Ile), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- N113K (p.Asn113Lys), rs1323690490, gnomAD 18-12793534-TTTTG, CADD 4.97
- N113N (p.Asn113Asn), rs1459651713, gnomAD 18-12793538-G-A, CADD 8.55
- N113S (p.Asn113Ser), rs1241646689, gnomAD 18-12793539-T-C, CADD 9.66
- R114C (p.Arg114Cys), rs771096169, NCI-TCGA Cosmic COSV5899, cosmic curated COSV58998, ExAC rs771096169, REVEL 0.85, CADD 29.50, Variant assessed as somatic; moderate impact.
- R114H (p.Arg114His), rs145657672, cosmic curated COSV58996, ESP rs145657672, ExAC rs145657672, REVEL 0.73, CADD 25.10, Variant assessed as somatic; moderate impact.
- R114K (p.Arg114Lys), rs747603845, gnomAD 18-12788145-C-T, CADD 5.33
- R114G (p.Arg114Gly), gnomAD 18-12788146-T-C, CADD 0.97
- R114T (p.Arg114Thr), rs777156011, gnomAD 18-12793538-GTTTC, CADD 8.85
- I115T (p.Ile115Thr), ExAC rs777852241, TOPMed rs777852241, gnomAD rs777852241, REVEL 0.28, CADD 21.10
- I115V (p.Ile115Val), rs1598716290, gnomAD 18-12788134-T-C, CADD 4.39
- E117* (p.Glu117Ter), gnomAD rs1188747865
- K118E (p.Lys118Glu), TOPMed rs2042646738, Uncertain significance, not specified
- S120* (p.Ser120Ter), ExAC rs758414586, gnomAD rs758414586, CADD 42.00
- S120L (p.Ser120Leu), cosmic curated COSV58998, ExAC rs758414586, gnomAD rs758414586, REVEL 0.56, CADD 25.50
- S120Y (p.Ser120Tyr), gnomAD 18-12793527-G-T, CADD 10.60
- p.Ser110 Phe111del, rs2041047237, gnomAD 18-12793528-AAAAA, CADD 7.89
- S120R (p.Ser120Arg), rs2041047618, gnomAD 18-12793534-T-G, CADD 1.97
- S120G (p.Ser120Gly), rs1192587258, gnomAD 18-12793552-T-C, CADD 13.90
- V121A (p.Val121Ala), gnomAD rs1290556737, REVEL 0.46, CADD 26.80
- C123Y (p.Cys123Tyr), TOPMed rs1400499894, gnomAD rs1400499894
- A124A (p.Ala124Ala), rs1218681401, gnomAD 18-12788117-A-G, CADD 6.09
- A124D (p.Ala124Asp), gnomAD 18-12788118-G-T, CADD 1.98
- A124S (p.Ala124Ser), rs183599904, gnomAD 18-12788119-C-A, CADD 2.42
- A124T (p.Ala124Thr), rs183599904, gnomAD 18-12788119-C-T, CADD 3.10
- Y126C (p.Tyr126Cys), gnomAD rs1354030120, REVEL 0.95, CADD 31.00
- Y126H (p.Tyr126His), TOPMed rs2042436499, gnomAD rs2042436499, REVEL 0.93, CADD 29.10
- D130G (p.Asp130Gly), gnomAD rs1280858319
- D131N (p.Asp131Asn), Ensembl rs2042435956, REVEL 0.28, CADD 22.60
- Q132H (p.Gln132His), rs756443279, ClinGen CA296753533, ClinVar RCV004179622, ExAC rs756443279, REVEL 0.21, CADD 9.95, Uncertain significance, not specified
- Q132K (p.Gln132Lys), gnomAD 18-12788128-G-T, CADD 8.87
- E133K (p.Glu133Lys), TOPMed rs1669577247
- E133V (p.Glu133Val), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- M134L (p.Met134Leu), TOPMed rs2042435577
- L135M (p.Leu135Met), rs750105074, ClinGen CA8898781, ClinVar RCV004264401, ExAC rs750105074, REVEL 0.14, CADD 14.90, Uncertain significance, not specified
- L135L (p.Leu135Leu), gnomAD 18-12788141-C-T, CADD 8.30
- F136L (p.Phe136Leu), 1000Genomes rs142645165, ESP rs142645165, ExAC rs142645165, TOPMed rs142645165, REVEL 0.34, CADD 23.30
- T139A (p.Thr139Ala), gnomAD rs1400124644, REVEL 0.47, CADD 22.40
- F141C (p.Phe141Cys), gnomAD rs1352097620
- F141L (p.Phe141Leu), rs1223343262, gnomAD 18-12788085-TAACT, CADD 3.85
- F141V (p.Phe141Val), rs1055535966, gnomAD 18-12788092-A-C, CADD 13.00
- S142T (p.Ser142Thr), TOPMed rs1213254112, gnomAD rs1213254112, REVEL 0.19, CADD 10.30
- V143I (p.Val143Ile), rs1272020535, gnomAD 18-12788116-C-T, CADD 0.39
- K144T (p.Lys144Thr), TOPMed rs2042434710
- K144E (p.Lys144Glu), rs1344158837, gnomAD 18-12788113-T-C, CADD 0.94
Public PTPN2 analysis runs
- PTPN2 analysis run — PTPN2 (651 variants) — completed 2026-08-21